Literature DB >> 1105793

Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia.

J Laszlo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1105793

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


× No keyword cloud information.
  25 in total

1.  Objective, planimetry-based assessment of megakaryocyte histological pictures in Philadelphia-chromosome-negative chronic myeloproliferative disorders: a perspective for a valuable adjunct diagnostic tool.

Authors:  Zbigniew Rudzki; Rafał Kawa; Krzysztof Okoñ; Ewa Szczygieł; Jerzy Stachura
Journal:  Virchows Arch       Date:  2005-10-12       Impact factor: 4.064

2.  Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome.

Authors:  E Montefusco; G Alimena; F Lo Coco; M R De Cuia; Y Z Wang; M A Aloe Spiriti; F Mancini; M Cedrone; M Mancini; F Mandelli
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

3.  Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan.

Authors:  Katsuto Takenaka; Kazuya Shimoda; Naoyuki Uchida; Taizo Shimomura; Koji Nagafuji; Tadakazu Kondo; Hirohiko Shibayama; Takehiko Mori; Kensuke Usuki; Taichi Azuma; Yutaka Tsutsumi; Junji Tanaka; Hitomi Dairaku; Keitaro Matsuo; Keiya Ozawa; Mineo Kurokawa; Shunya Arai; Koichi Akashi
Journal:  Int J Hematol       Date:  2016-10-19       Impact factor: 2.490

4.  Extramedullary hematopoiesis mimicking acute appendicitis: a rare complication of idiopathic myelofibrosis.

Authors:  Gülsüm Ozlem Elpek; Sevgi Bozova; Gülgün Erdoğan; Kamil Temizkan; Mehmet Oğüş
Journal:  Virchows Arch       Date:  2006-08       Impact factor: 4.064

5.  Histomorphometry of bone marrow biopsies in primary osteomyelofibrosis/-sclerosis (agnogenic myeloid metaplasia)--correlations between clinical and morphological features.

Authors:  J Thiele; B Hoeppner; R Zankovich; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

6.  Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia.

Authors:  Andrea Piccin; Michael Steurer; Manfred Mitterer; Elisabeth Maria Blöchl; Luigi Marcheselli; Irene Pusceddu; Alessandra Marabese; Irene Bertozzi; Daisy Corvetta; Maria Luigia Randi; Elena Elli; Enrico Maria Pogliani; Dino Veneri; Omar Perbellini; Mauro Krampera; Enrica Pacquola; Michele Gottardi; Mario Tiribelli; Anna Guella; Barbara Innella; Paolo Vivaldi; Ercole De Biasi; Rosaria Sancetta; Roberta Rocconi; Renato Bassan; Filippo Gherlinzoni; Giovanni Pizzolo; Günther Gastl; Sergio Cortelazzo
Journal:  Intern Emerg Med       Date:  2015-01-14       Impact factor: 3.397

7.  Extramedullary haemopoiesis in the small bowel.

Authors:  B K Sharma; R E Pounder; J P Cruse; S M Knowles; A A Lewis
Journal:  Gut       Date:  1986-07       Impact factor: 23.059

8.  Polycythemia vera: electron microscopy of the bone marrow in 10 non-treated patients. A thin section and freeze-fracture study.

Authors:  J Thiele; W Stangel; K F Vykoupil; A Georgii
Journal:  Blut       Date:  1979-05

9.  The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.

Authors:  Zbigniew Rudzki; Tomasz Sacha; Anastazja Stój; Sylwia Czekalska; Małgorzata Wójcik; Aleksander B Skotnicki; Barbara Grabowska; Andrzej Zduńczyk; Krzysztof Okoń; Jerzy Stachura
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

10.  Ascites progressing to an abdominal mass due to extramedullary hematopoiesis in a patient with agnogenic myeloid metaplasia (AMM).

Authors:  J B Marshall; D A Burnett; J C Anderson; R K Zetterman
Journal:  Dig Dis Sci       Date:  1983-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.